LUND, Sweden, Dec. 17, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), today announced positive full results from the 15-HMedIdeS-09 single arm Phase 2 study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome (GBS) and an indirect...
Hence then, the article about hansa biopharma announces positive full results from 15 hmedides 09 phase 2 study and comparative analysis of imlifidase in patients with guillain barre syndrome was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Hansa Biopharma announces positive full results from 15-HMedIdeS-09 Phase 2 study and comparative analysis of imlifidase in patients with Guillain-Barré Syndrome )
Also on site :
- US cable outlines new ‘construct’ to control Strait of Hormuz – media
- ’80s Thrash Metal Frontman, Who Survived Rare Cancer, Announces New Project
- Help! My Friend Volunteered to Dog-Sit for Months. I’m Horrified by What I Caught Him Doing on My Secret Camera.